Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hehlmann

Showing results (281-290 of 310) with videos related to

Pageof 31
Sort By:
Leukemia|July 31, 2004
Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemiaG Buesche, M Freund, R Hehlmann, et al.
Leukemia|September 13, 2003
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alphaU Berger, G Engelich, O Maywald, et al.
Leukemia|February 9, 2016
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or bothS Koschmieder, T I Mughal, H C Hasselbalch, et al.
Blood|March 21, 1998
Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study GroupR P Gale, R Hehlmann, M J Zhang, et al.
Leukemia|April 29, 2016
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaJ L Steegmann, M Baccarani, M Breccia, et al.
Leukemia|September 11, 2009
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCGE Lengfelder, C Haferlach, S Saussele, et al.
Deutsche Medizinische Wochenschrift (1946)|October 21, 2006
[Clinical research at the European LeukemiaNet]S Saussele, K Adam, A Hochhaus, et al.
Blood|November 26, 1999
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedureR Hehlmann, A Hochhaus, H J Kolb, et al.
Bone Marrow Transplantation|May 1, 1996
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study GroupR Hehlmann, H Heimpel, D K Hossfeld, et al.
Leukemia|August 15, 2000
Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative GroupE Lengfelder, A Reichert, C Schoch, et al.
Pageof 31

Showing results (281-290 of 310) with videos related to

Sort By:
Pageof 31
Leukemia|July 31, 2004
Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemiaG Buesche, M Freund, R Hehlmann, et al.
Leukemia|September 13, 2003
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alphaU Berger, G Engelich, O Maywald, et al.
Leukemia|February 9, 2016
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or bothS Koschmieder, T I Mughal, H C Hasselbalch, et al.
Blood|March 21, 1998
Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study GroupR P Gale, R Hehlmann, M J Zhang, et al.
Leukemia|April 29, 2016
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaJ L Steegmann, M Baccarani, M Breccia, et al.
Leukemia|September 11, 2009
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCGE Lengfelder, C Haferlach, S Saussele, et al.
Deutsche Medizinische Wochenschrift (1946)|October 21, 2006
[Clinical research at the European LeukemiaNet]S Saussele, K Adam, A Hochhaus, et al.
Blood|November 26, 1999
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedureR Hehlmann, A Hochhaus, H J Kolb, et al.
Bone Marrow Transplantation|May 1, 1996
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study GroupR Hehlmann, H Heimpel, D K Hossfeld, et al.
Leukemia|August 15, 2000
Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative GroupE Lengfelder, A Reichert, C Schoch, et al.
Pageof 31